In January 2021, tiragolumab (anti-TIGIT) combined with atezolizumab was approved by FDA for the treatment of metastatic non-small cell lung cancer patients with PD-L1 but without EGFR/ALK genome abnormalities. This evidence concerns the gene ALK and non-small cell lung carcinoma.